ABBV - AbbVie Inc.

229.89
1.100   0.478%

Share volume: 1,744,910
Last Updated: 12-24-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$228.79
1.10
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
62%
Profitability 65%
Dept financing 50%
Liquidity 40%
Performance 67%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.87%
1 Month
0.98%
3 Months
4.21%
6 Months
23.07%
1 Year
28.29%
2 Year
48.68%
Key data
Stock price
$229.89
P/E Ratio 
170.06
DAY RANGE
$228.98 - $230.80
EPS 
$1.32
52 WEEK RANGE
$164.39 - $244.81
52 WEEK CHANGE
$29.14
MARKET CAP 
406.101 B
YIELD 
2.81%
SHARES OUTSTANDING 
1.767 B
DIVIDEND
$1.64
EX-DIVIDEND DATE
10-15-2025
NEXT EARNINGS DATE
07-24-2025
BETA 
0.06
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,509,167
AVERAGE 30 VOLUME 
$5,482,878
Company detail
CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

Recent news